A SARS-CoV-2 Outbreak Among Nursing Home Residents Vaccinated with a Booster Dose of mRNA COVID-19 Vaccine

This study describes a SARS-CoV-2 outbreak caused by the Delta (B.1.617.2) variant in a nursing home in Central Italy during October–November 2021. Trained interviewers collected data from residents, staff, and administration officers with an agreed informed consent procedure. Thirty-two (44.5%) out...

Full description

Saved in:
Bibliographic Details
Published in:Journal of community health 2022-08, Vol.47 (4), p.598-603
Main Authors: Ripabelli, Giancarlo, Sammarco, Michela Lucia, Rezza, Giovanni, D’Amico, Antonio, De Dona, Roberta, Iafigliola, Mariagrazia, Parente, Albino, Samprati, Nicandro, Santagata, Arturo, Adesso, Carmen, Natale, Anna, Di Palma, Michela Anna, Cannizzaro, Fabio, Dentizzi, Cosimo, Stefanelli, Paola, Tamburro, Manuela
Format: Article
Language:English
Subjects:
Community and Environmental Psychology
Coronaviruses
COVID-19
COVID-19 vaccines
Ethics
Health Promotion and Disease Prevention
Informed consent
Medical personnel
Medicine
Medicine & Public Health
mRNA
Nurses
Nursing homes
Original Paper
Outbreaks
Residential Institutions
Severe acute respiratory syndrome coronavirus 2
Signs and symptoms
Vaccines
Viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study describes a SARS-CoV-2 outbreak caused by the Delta (B.1.617.2) variant in a nursing home in Central Italy during October–November 2021. Trained interviewers collected data from residents, staff, and administration officers with an agreed informed consent procedure. Thirty-two (44.5%) out of 72 residents (median age 89 years) and six (26.1%) of 23 healthcare workers were found to be infected with SARS-CoV-2. Infections occurred more often among residents with a higher index of independence in daily living activities, suggesting an increased risk for those with more interactions. Twenty-five infected residents (78.1%) received the booster dose of mRNA anti-COVID-19 vaccine > 7 days before SARS-CoV-2 onset. Half of the infected residents had mild symptoms, and only three required hospitalisation, one of whom died from COVID-19 complications. The study underlines the effectiveness of a booster dose in providing a high protection against severe disease and hospitalisation even among vulnerable individuals infected with the Delta variant of concern.
ISSN:0094-5145
1573-3610
DOI:10.1007/s10900-022-01082-8